NCT06544577 - Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC | Biotech Hunter

Enrollment

350

Participants

Timeline

Start Date

July 13, 2024

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2026

Conditions

ESR1 Gene MutationAdvanced Breast CancerSafety

Interventions

DRUG

ELacestrant

345 mg/day once daily oral dosing

Trial Locations (1)

RECRUITING

Hainan Hospital of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (Boao Research Hospital, Hainan), Qionghai